ACHV 250117 5.00P (ACHV250117P5000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ACHV250117P5000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 10 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Achieve Life Sciences Appoints DR. Kristen Slaoui and Nancy Phelan to Its Board of Directors
ReutersJan 10 08:30 ET
Press Release: Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to Its Board of Directors
Dow JonesJan 10 08:30 ET
Oppenheimer Sticks to Its Buy Rating for Achieve Life Sciences (ACHV)
TipRanksJan 8 07:36 ET · Ratings
Achieve Life Sciences Reaches Milestone in Clinical Trial for Smoking Cessation Drug
MT NewswiresJan 7 11:36 ET
JonesTrading Maintains Achieve Life(ACHV.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsJan 7 10:31 ET · Ratings
Achieve Life Sciences (ACHV) Gets a Buy From JonesTrading
TipRanksJan 7 10:15 ET · Ratings

Comments

Jaguar8

Jan 7 07:35

NEWS

$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Tuesday, 7th January at 8:30 am
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified
Planned Cytisinicline NDA Submission on...

MindOverMatter

Aug 13, 2024 19:03

$Achieve Life (ACHV.US)$

Jaguar8

May 29, 2024 07:01

NEWS

$Achieve Life (ACHV.US)$
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...

Jaguar8

May 6, 2024 11:33

$Achieve Life (ACHV.US)$
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Meltyy

Mar 20, 2024 10:18

Biotech Stock News 3/20

$Annovis Bio (ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...